No Data
No Data
HKEX Stock Market Live | Ec Healthcare (02138) fell more than 6%, leading the decline in the medical beauty concept. The demand for medical beauty is temporarily under pressure, and the growth in the second quarter is slightly under pressure.
Aesthetic medicine stocks collectively declined, as of press time, ec healthcare (02138) fell by 5.45%, at HKD 1.04; shanghai haohai biological technology (06826) fell by 4.56%, at HKD 30.35; sisram med (01696) fell by 3.69%, at HKD 3.13.
Aesthetic medicine stocks are under pressure, and Sisram Medical (01696) fell by 4.02%. Daiwa expects macro and policy factors to suppress the growth of cosmetic medicine companies in the second half of the year.
Aesthetic medicine concept stocks are under pressure, with Sisram Med (01696) falling 4.02%, Haohai Biotech (06826) falling 2.18%, Perfect Medical (01830) falling 1.92%, and Rui'er Group (06639) falling 1.39%. On the news side, Morgan Stanley's report pointed out that under the sustained anti-corruption factor in the mainland, the market is expected to have weak second-quarter performance of medical technology companies. Investors are concerned about the timing and scale of the upcoming central government's fiscal stimulus plan, which sets expectations for medical technology stocks for the second half of this year and next year. Meanwhile, macro and policy aspects
China's Medical Device Market Value Hits $179B, 90th CMEF in Shenzhen to Feature a Plethora of Technological Products
Sinolink Securities: The pharmaceutical sector is expected to see an improvement in market conditions in the third quarter, and overall growth expectations for the second half of the year are optimistic.
Sinolink Securities released a research report stating that considering the improvement in the medical insurance settlement cycle, the expectation of policy improvement, and the recovery performance of the industry, as well as the fact that institutional medicine hold positions are at a low level, the medical sector will usher in an improved market situation in Q3.
BOC International: Continued prosperity of upstream medical beauty manufacturers opens up space for external expansion.
According to the research reports released by BOC International, the performance of leading medical and aesthetic companies is still maintaining good growth, and the average product price has not shown any price reduction pressure. The constantly enriched product matrix is expected to bring growth in the future.
Shareholders Will Probably Hold Off On Increasing Sisram Medical Ltd's (HKG:1696) CEO Compensation For The Time Being
No Data